2024
Hemery J, Tattevin P, Marshall E, Annequin M, Chiarabini T, Dournon N, Freire Maresca A, Ghosn J, Isernia V, Michard F, Perrineau S, Rincon G, Spire B, De Truchis P, Grabar S., for the ANRS CO4 FHDH study group. SFLS 2024 Délai de mise sous traitement chez les femmes transgenres (1997-2022).
Lanoy E., Duvivier C., De Castro N., Abgrall S., Bregigeon-Ronot S., Caby F., Deschanvres C., Ghosn J., Karmochkine M., Katlama C., Launay
O., Pradier C., Reynes J., Salmon D., Costagliola D., Grabar S., for the ANRS CO4 FHDH study group. Glasgow HIV 2024 Switching from integrase strand transfer inhibitors (INSTIs) based triple therapy to dual therapy in people living with HIV-1 infection: the French Hospital Database on HIV (ANRS CO4 FHDH) real-life experience
Potard V., Gassama M., Lanoy E., Abel S., Bani-Sadr F., Becker A., Bregigeon S., Caby F.6 Denis B., de Truchis P., Duvivier, C., Katlama C., Lamaury I., Martin-Blondel G., Meynard JL., Piroth L., Robineau O., Tattevin P., Ursenbach A., Costagliola D., Grabar S, for the ANRS CO4 FHDH study group. CROI_2024_Impact of accessing care at an advanced stage on mortality in PWH in France, 2002-2016
Pantazis N., Costagliola D., Sighem A. V., Jarrin I., Meyer L., Sabin C., Carlander C., Gill J., Tariq S., Spire B., Burns F, Ruiz-Burga E., Porter K., Touloumi G., for CASCADE Collaboration. CROI 2024_Temporal Trends in CD4 Cell Count Soon After Seroconversion and HIV-RNA Viral Set-Point
Pantazis N., Grabar S., Van der Valk M., Sabin C., Jarrin I., Meyer L., Carlander C., Gill J., Tariq S., Volny Anne A., Burns F., Ruiz-Burga E., Touloumi G., Porter K., for CASCADE Collaboration. CROI 2024_Weight Gain After Initiating ART Close to HIV Seroconversion: Is There a “Return to Health” Effect?
2023
Potard V., Lakrout P., Marshall E., Cadranel J., Jacomet C., Katlama C., Makinson A., Lambotte O., Lavolé A., Palich R.1,, Ronot S., Spano JP., Costagliola D., Grabar S., for the ANRS CO4 FHDH study group. Notification rates of cancers in the ANRS CO4 FHDH cohort
Potard V., Gassama M., Lanoy E., Abel S., Bani-Sadr F., Becker A., Bregigeon S., Caby F.6 Denis B., de Truchis P., Duvivier
C., Katlama C., Lamaury I., Martin-Blondel G., Meynard JL., Piroth L., Robineau O., Tattevin P., Ursenbach A., Costagliola D., Grabar S, for the ANRS CO4 FHDH study group. Impact d’une prise en charge tardive sur la mortalité des PVVIH
2022
Choufany M., Marshall E., Maria A., Mayeux A., Spire B., Grabar S., Costagliola D. Éligibilité à l’assurance emprunteur selon la grille de référence AERAS de 2017, 2021 et 2022 des PVVIH suivies dans la base ANRS CO4 FHDH
Marty L, Diawara Y, Rachas A, Grabar S, Costagliola D, Supervie V. Projection of age and time since ART initiation of persons living with HIV in 2030 : estimates for France
Choufany M., Weiss L., Makinson A. , Roul H. , Livrozet J-M. , Pourcher V., Melica G. , Rioux C. , Viard J-P., Marshall E. , Grabar S. , Costagliola D. Decline In CD4 Counts And Risk Of Severe Morbidity In PLHIV After Initiating CART
2021
Requena M, Grabar S, Costagliola D and Lacombe K. Higher all-cause mortality in individuals living with HIV cured of HCV by direct-acting antivirals compared to HIV mono-infection despite controlled HIV: Results from the ANRS-CO4 FHDH cohort
